eIF3a基因多态性与卵巢癌铂类药物化疗敏感性的相关研究

发布时间：2018-08-30 15:11

【摘要】：目的：通过检测卵巢癌中eIF3a表达和eIF3a基因的多态性,研究其与卵巢癌铂类药物化疗敏感性的关系。方法：应用q-PCR技术检测52例卵巢癌组织与10例正常卵巢组织中eIF3a mRNA表达水平,比较卵巢癌组织和正常卵巢组织、不同分化程度的卵巢癌中、卵巢癌耐药组和敏感组间eIF3a mRNA的表达差异；应用MassARRAY技术检测57例卵巢癌血液标本中eIF3a基因的多态性位点分型,分析这些多态性位点基因型与卵巢癌铂类化疗敏感性的相关性；应用SPSS19.0软件对数据进行统计分析。结果：1. eIF3a mRNA在卵巢癌组织与正常卵巢组织中均有表达,其相对表达量的均值分别为0.33±0.16、0.20±0.05,癌组织中的表达水平高于正常卵巢组织中的表达水平,差异有统计学意义(P0.05)。 2. eIF3a mRNA在高、中、低分化三组卵巢癌中的相对表达量均值分别为0.28±0.14、0.32±0.17、0.34±0.17,差异无统计学意义(P0.05)。 3. eIF3a mRNA在卵巢癌铂类药物敏感组和耐药组中的相对表达量均值分别为0.32±0.18、0.35±0.16,差异无统计学意义(P0.05)。 4.在卵巢癌铂类耐药组和敏感组中,eIF3a基因rs3824830位点的AA型频率分别为44.0%、56.0%,GA型频率分别33.33%、66.67%,GG型频率分别为77.78%、22.22%,平衡了年龄、分期后,差异无统计学意义(P0.05)。 5.在卵巢癌铂类耐药组和敏感组中,eIF3a基因rs77382849位点的CC型频率分别为42.85%、57.15%,TC型频率分别为57.14%、42.86%,平衡了年龄、分期后,差异无统计学意义(P0.05)。 6.在卵巢癌铂类耐药组和敏感组中,eIF3a基因rs10787899位点的GG型频率分别为60%、40%,GA型频率分别为40.74%、59.26%,AA型频率分别为33.33%、66.67%,平衡了年龄、分期后,差异无统计学意义(P0.05)。 7.在卵巢癌铂类耐药组和敏感组中,eIF3a基因rs3740556位点均为GG型。结论：1.eIF3a可能成为卵巢癌诊断的分子标志物。 2.浆液性卵巢癌患者中,除eIF3a基因rs3740556位点外,rs3824830、rs77382849、rs10787899位点均检测出突变基因型,但这些基因型与卵巢癌铂类药物化疗敏感性无明显相关性。
[Abstract]:Aim: to study the relationship between the expression of eIF3a and the polymorphism of eIF3a gene in ovarian cancer. Methods: q-PCR technique was used to detect the expression of eIF3a mRNA in 52 cases of ovarian cancer and 10 cases of normal ovarian tissues. The expression of eIF3a mRNA was different between drug-resistant ovarian cancer and sensitive ovarian cancer, and the polymorphism loci of eIF3a gene were detected by MassARRAY technique in 57 ovarian cancer blood samples, and the correlation between these polymorphism loci and platinum chemosensitivity of ovarian cancer was analyzed. The data were analyzed by SPSS19.0 software. Results 1. EIF3a mRNA was expressed in both ovarian cancer and normal ovarian tissues. The mean relative expression level of eIF3a mRNA was 0.33 卤0.160.20 卤0.05, respectively. The expression level of eIF3a mRNA in cancer was higher than that in normal ovarian tissue. The difference was statistically significant (P0.05). 2. EIF3a mRNA in high, middle, The mean relative expression of eIF3a mRNA in ovarian cancer was 0.28 卤0.140.32 卤0.170.34 卤0.17, respectively (P0.05). 3. The mean relative expression of eIF3a mRNA in platinum-sensitive and drug-resistant ovarian cancer was 0.32 卤0.180.35 卤0.16, respectively. Academic significance (P0.05). 4. In the platinum-resistant and sensitive groups of ovarian cancer, the AA type frequencies of the rs3824830 locus of eIF3a gene were 44.0 and 56.0, respectively, and the frequencies of GA type were 33.33 and 66.67, respectively. The frequencies of GG type were 77.7878 and 22.22, respectively. There was no significant difference after stage (P0.05). In the platinum-resistant and sensitive groups of ovarian cancer, the CC type frequencies of the rs77382849 locus of eIF3a gene were 42.85 and 57.15, respectively. The frequencies of TC type were 57.14 and 42.86, respectively. After balancing the age and stage, the difference was not statistically significant (P0.05). In the platinum-resistant and sensitive groups of ovarian cancer, the GG type frequencies of the rs10787899 locus of eIF3a gene were 60 and 40, respectively, and the frequencies of GA type were 40.74 and 59.26, respectively. The frequency of AA type was 33.333366.67. After balancing the age, there was no significant difference after staging (P0.05). The rs3740556 loci of eIF3a gene in platinum-resistant and sensitive groups of ovarian cancer were all GG type. Conclusion: 1. EIF3a may be a molecular marker for diagnosis of ovarian cancer. Mutation genotypes were detected at rs3824830 rs77382849 rs10787899 except the rs3740556 site of eIF3a gene in patients with serous ovarian cancer, but there was no significant correlation between these genotypes and the chemotherapeutic sensitivity of platinic drugs in ovarian cancer.
【学位授予单位】：中南大学
【学位级别】：硕士
【学位授予年份】：2014
【分类号】：R737.31

【共引文献】